A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2006
12/28/2006	US20060292123 Adeno-associated virus-mediated delivery of GDNF to skeletal muscles
12/28/2006	DE102005029468A1 Use of an exogenous or endogenous inhibitor of N-methyltransferase for the manufacture of a medicament for therapy and prophylaxis of Parkinson's syndrome
12/28/2006	DE102005028845A1 New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
12/28/2006	CA2633030A1 Intralesional treatment of psoriasis
12/28/2006	CA2620946A1 Amniotic cells and methods for use thereof
12/28/2006	CA2613253A1 Combination comprising amino alcohol derivatives as immunosuppressants
12/28/2006	CA2613249A1 Crystals of phenylalanine derivatives, production method thereof and use thereof
12/28/2006	CA2613210A1 Multiple sclerosis therapy and diagnosis
12/28/2006	CA2613001A1 Quinoline 3 -sulfonate esters as nk3 receptor modulators
12/28/2006	CA2612922A1 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
12/28/2006	CA2612738A1 Solid pharmaceutical composition comprising (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman
12/28/2006	CA2612726A1 Halogenated pyrazolo [1,5-a]pyrimidines, processes, uses as gaba-a receptors ligand, compositions and intermediates
12/28/2006	CA2612495A1 Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders
12/28/2006	CA2612491A1 Tricyclic opioid modulators
12/28/2006	CA2612409A1 Naphthyridine compounds
12/28/2006	CA2612268A1 Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists
12/28/2006	CA2612262A1 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
12/28/2006	CA2612133A1 New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
12/28/2006	CA2612109A1 Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
12/28/2006	CA2612090A1 Tablet containing hardly soluble active ingredient
12/28/2006	CA2611936A1 Botulinum toxin and the treatment of primary disorders of mood and affect
12/28/2006	CA2610828A1 Heterocyclic aspartyl protease inhibitors, preparation and use thereof
12/28/2006	CA2610812A1 Aspartyl protease inhibitors
12/28/2006	CA2610742A1 Pyrimidine derivatives for the treatment op gaba b mediated nervous system disorders
12/28/2006	CA2610617A1 The preparation and use of protease inhibitors
12/28/2006	CA2610326A1 Substituted pyrr0lidin-2-0nes , piperidin-2-0nes and isothiazolidine-1, 1-dioxides, their use as kv1.5 potassium channel blockers and pharmaceutical preparations comprising them
12/28/2006	CA2610102A1 New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions
12/28/2006	CA2610075A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
12/28/2006	CA2610036A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609994A1 New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
12/28/2006	CA2609993A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609990A1 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609582A1 Aspartyl protease inhibitors
12/28/2006	CA2609562A1 Macrocyclic heterocyclic aspartyl protease inhibitors
12/28/2006	CA2609077A1 Lgi, lingo and p75ntr family members: novel modulators of neuronal growth
12/28/2006	CA2608319A1 Substituted spiro-compounds and the use thereof for producing medicaments
12/27/2006	EP1736544A1 Gm1 PROMOTER AND USE THEREOF
12/27/2006	EP1736541A1 Novel galectin 9 modification protein and use thereof
12/27/2006	EP1736478A1 Methods and compositions for treating flaviviruses and pestiviruses
12/27/2006	EP1736474A1 Piperidine derivative
12/27/2006	EP1736470A2 Pyrimidine derivatives as CB2 cannabinoid receptor modulators
12/27/2006	EP1736469A2 Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol
12/27/2006	EP1736468A2 Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation
12/27/2006	EP1736172A1 Method of utilizing organic cation transporter oct3-related molecule for treating mental diseases such as depression, anxiety neurosis, drug addiction and the like
12/27/2006	EP1736162A1 Remedy for prion disease and method of producing the same
12/27/2006	EP1736160A1 Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
12/27/2006	EP1736158A2 Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts
12/27/2006	EP1736155A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
12/27/2006	EP1736154A1 Use of PP-1 inhibitors to prevent missplicing events
12/27/2006	EP1736150A2 Sertraline salts and sustained-release dosage forms of sertraline
12/27/2006	EP1735443A2 RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/27/2006	EP1735332A1 Azacyclosteroid histamine-3 receptor ligands
12/27/2006	EP1735308A1 Fused ring azadecalin glucocorticoid receptor modulators
12/27/2006	EP1735306A2 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
12/27/2006	EP1735305A2 3-quinuclidinyl heteroatom bridged biaryl derivatives
12/27/2006	EP1735302A1 4-amino-piperidine derivatives as monoamine uptake inhibitors
12/27/2006	EP1735301A1 Pyridine derivatives as cannabinoid receptor modulators
12/27/2006	EP1735299A1 Tertrahydrobenzazepines as histamine h3 receptor ligands
12/27/2006	EP1735293A2 Substituted hydroxyethylamine aspartyl protease inhibitors
12/27/2006	EP1735292A1 Thiazole-amine compounds for the treatment of neurodegenerative disorders
12/27/2006	EP1735287A1 Therapeutic agents
12/27/2006	EP1735278A1 Histamine h3 receptor agents, preparation and therapeutic uses
12/27/2006	EP1735057A2 Method and compositions for treatment of chronic neuropathic pain
12/27/2006	EP1735008A2 Tetanus toxin fusion protein for visualization of active synapses
12/27/2006	EP1734989A1 Novel use of antisecretory factor
12/27/2006	EP1734981A1 TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS
12/27/2006	EP1734980A1 Use of peptidic compounds for the prophylaxis and treatment of chronic headache
12/27/2006	EP1734974A1 D-ribose for improving depression-like symptoms
12/27/2006	EP1734962A2 Compositions and methods for modulating gated ion channels
12/27/2006	EP1734961A2 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
12/27/2006	EP1734959A2 Method of treating schizophrenia and/or glucoregulatory abnormalities
12/27/2006	EP1734957A2 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
12/27/2006	EP1734956A1 Treatment of impaired respiratory function with gaboxadol
12/27/2006	EP1734942A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
12/27/2006	EP1734940A1 Combination of deramciclane and opoids as analgesics
12/27/2006	EP1734820A2 Imidazopyrazines, imidazopyridines, and imidazopyrimidines as crf1 receptor ligands
12/27/2006	EP1653963B1 Nasal pharmaceutical piribedil composition
12/27/2006	EP1611098B1 Compounds having activity at 5ht2c receptor and uses thereof
12/27/2006	EP1551992B1 Screening molecules with anti-prion activity: kits, methods and screened molecules
12/27/2006	EP1480961B1 Glutaminyl based dpiv inhibitors
12/27/2006	EP1443925B1 Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
12/27/2006	EP1436267B1 Lactam derivatives as antagonists for human 11cby receptors
12/27/2006	EP1392276B1 Potentiation of therapeutic effects of polyunsaturated fatty acids
12/27/2006	EP1381604B1 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
12/27/2006	EP1368317B1 Tryptase inhibitors
12/27/2006	EP1358209B1 Crystallization of igf-1
12/27/2006	EP1354047B1 Methods for screening compounds that modulate lipid metabolism
12/27/2006	EP1332372B1 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
12/27/2006	EP1299374B1 Novel non-psychotropic cannabinoids
12/27/2006	EP1231898B1 Apparatus and method for preparing microparticles
12/27/2006	EP1165100B1 Methods of treating schizophrenia
12/27/2006	EP1073739B1 Cd40-interacting and traf-interacting proteins
12/27/2006	EP0998495B1 Amyloid beta protein (globular assembly and uses thereof)
12/27/2006	EP0973804B1 Anti-vegf antibodies
12/27/2006	CN1886423A Glycoisoforms of adiponectin and uses thereof
12/27/2006	CN1886397A 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
12/27/2006	CN1886392A Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
12/27/2006	CN1886379A Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
12/27/2006	CN1886375A Piperidine compound and method for producing same
12/27/2006	CN1886372A 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for alzheimer's disease and related conditions

1 ... 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 ... 1833